公开(公告)号：US08718996B2

公开(公告)日：2014-05-06

申请号：US13836064

申请日：2013-03-15

Applicant: Biodesix, Inc.

Inventor： Joanna Röder ,  Heinrich Röder ,  Julia Grigorieva

IPC: G01N33/48 ,  G01N33/50 ,  G06G7/58 ,  G06G7/48 ,  G06F19/00

CPC classification number: H01J49/26 ,  G01N33/57488 ,  G01N33/6848 ,  G01N2800/52 ,  G06F19/34 ,  G06F19/707 ,  G16H50/20 ,  G16H50/50 ,  H01J49/0027 ,  Y02A90/26

Abstract: A testing method for identification whether a cancer patient is a member of a group or class of cancer patients that are not likely to benefit from administration of a platinum-based chemotherapy agent, e.g., cisplatin, carboplatin or analogs thereof, either alone or in combination with other non-platinum chemotherapy agents, e.g., gemcitabine and paclitaxel. This identification can be made in advance of treatment. The method uses a mass spectrometer obtaining a mass spectrum of a blood-based sample from the patient, and a computer operating as a classifier and using a stored training set comprising class-labeled spectra from other cancer patients.

公开(公告)号：US20140012514A1

公开(公告)日：2014-01-09

申请号：US13836064

申请日：2013-03-15

Applicant: BIODESIX, INC.

Inventor： Joanna Röder ,  Heinrich Röder ,  Julia Grigorieva

IPC: G06F19/00 ,  H01J49/00

CPC classification number: H01J49/26 ,  G01N33/57488 ,  G01N33/6848 ,  G01N2800/52 ,  G06F19/34 ,  G06F19/707 ,  G16H50/20 ,  G16H50/50 ,  H01J49/0027 ,  Y02A90/26

Abstract: A testing method for identification whether a cancer patient is a member of a group or class of cancer patients that are not likely to benefit from administration of a platinum-based chemotherapy agent, e.g., cisplatin, carboplatin or analogs thereof, either alone or in combination with other non-platinum chemotherapy agents, e.g., gemcitabine and paclitaxel. This identification can be made in advance of treatment. The method uses a mass spectrometer obtaining a mass spectrum of a blood-based sample from the patient, and a computer operating as a classifier and using a stored training set comprising class-labeled spectra from other cancer patients.

公开(公告)号：US20130131996A1

公开(公告)日：2013-05-23

申请号：US13741634

申请日：2013-01-15

Applicant: BIODESIX, INC.

Inventor： Joanna Röder ,  Julia Grigorieva ,  Heinrich Röder

IPC: A61B10/00 ,  G06F19/24 ,  G01N33/68

CPC classification number: A61B10/0041 ,  G01N33/57415 ,  G01N33/6848 ,  G01N33/6893 ,  G01N2333/485 ,  G01N2333/71 ,  G01N2800/52 ,  G06F19/24 ,  H01J49/00

Abstract: A mass-spectral method is disclosed for determining whether breast cancer patient is likely to benefit from a combination treatment in the form of administration of a targeted anti-cancer drug in addition to an endocrine therapy drug. The method obtains a mass spectrum from a blood-based sample from the patient. The spectrum is subject to one or more predefined pre-processing steps. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained. The values are used in a classification algorithm using a training set comprising class-labeled spectra and a class label for the sample is obtained. If the class label is “Poor”, the patient is identified as being likely to benefit from the combination treatment. In a variation, the “Poor” class label predicts whether the patient is unlikely to benefit from endocrine therapy drugs alone, regardless of the patient's HER2 status.

Abstract translation: 公开了用于确定乳腺癌患者是否可能以除了内分泌治疗药物之外的靶向抗癌药物的施用形式的组合治疗中受益的质谱方法。 该方法从患者的血液样品获得质谱。 光谱受一个或多个预定义的预处理步骤的限制。 获得在一个或多个预定义m / z范围内的光谱中所选特征的值。 这些值用于使用包括类标记光谱的训练集的分类算法，并且获得样本的类标签。 如果班级标签为“差”，患者被确定为可能从组合治疗中受益。 在一个变化中，“不良”类标签预测患者是否不太可能从单独的内分泌治疗药物中受益，无论患者的HER2状况如何。